bmi requirements for glp 1 Medicare GLP-1 Drug Coverage Indications for GLP-1/GIP RA Summary

These programs prioritize safety, transparency, and long-term outcomes instead of marketing hype

Our goal is transparencyno surprises

Notably, based on the results from part 1 of the ESSENCE trial, on 15 August 2025, the FDA approved semaglutide 2.4 mg for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)

Because these processes can emerge earlier or be more pronounced in people with HIV, this community can help us identify interventions that may improve healthspan more broadly. In a related pilot study published in npj Aging last month, Corley and another team of researchers found that taking semaglutide for 24 weeks: Reduced the rate of biological aging for 42% of participants with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD) also known as fatty liver disease as measured by the DunedinPACE epigenetic clock

That means you're not just satisfying your sweet tooth